Human CD300f/LMIR3 Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB2774

R&D Systems, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human, Mouse

Applications

Validated:

CyTOF-ready, Flow Cytometry, Immunocytochemistry

Cited:

Neutralization, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Rat IgG2B Clone # 234903

View all CD300f/LMIR3 Antibodies »

Product Specifications

Immunogen

Y3 rat myeloid cell line transfected with human CD300f/LMIR3

Specificity

Detects human CD300f/LMIR3 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human LMIR1, 2, 4, 5, 6, or recombinant mouse LMIR3 is observed.

Clonality

Monoclonal

Host

Rat

Isotype

IgG2B

Scientific Data Images for Human CD300f/LMIR3 Antibody

CD300f/LMIR3 antibody in Human PBMCs by Immunocytochemistry (ICC).

CD300f/LMIR3 in Human PBMCs.

CD300f/LMIR3 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Rat Anti-Human CD300f/LMIR3 Monoclonal Antibody (Catalog # MAB2774) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rat IgG Secondary Antibody (red; Catalog # NL013) and counterstained with DAPI (blue). Specific staining was localized to cell surfaces. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.

Applications for Human CD300f/LMIR3 Antibody

Application
Recommended Usage

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

0.25 µg/106 cells
Sample: Human whole blood monocytes

Immunocytochemistry

8-25 µg/mL
Sample: Immersion fixed human peripheral blood mononuclear cells (PBMCs)

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CD300f/LMIR3

CD300f, also known as CD300LF, LMIR3, IREM-1, CLM-1, IgSF13, DIgR1, and MAIR-V, is a 50‑60 kDa glycoprotein member of the immunoglobulin superfamily (1). Human CD300f consists of a 137 amino acid (aa) extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane segment, and a 113 aa cytoplasmic domain that contains multiple immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or ITIM-like sequences (2, 3). Alternate splicing generates additional isoforms that carry substituted C-terminal tails of varying lengths and sequences following the ECD or transmembrane segment (3). Within the ECD, human CD300f shares 43% aa sequence identity with mouse and rat CD300f. CD300f is expressed on the surface of dendritic cells, monocytes, granulocytes, and mast cells as well as on acute myeloid leukemia (AML) blasts (2‑4). Pervanadate treatment or antibody crosslinking of CD300f induces phosphorylation of tyrosine residues in the cytoplasmic domain and the subsequent recruitment of phosphatases SHIP, SHP-1, SHP-2, and the p85 alpha subunit of PI3K (2, 3, 5, 6). CD300f ligation can induce cell death and inhibit signaling through multiple receptors including Fc epsilon RI, LMIR4, SCF R, TLR2, TLR3, and TLR9 (3‑8). In contrast, it enhances TLR4-mediated signaling/cytokine production in mast cells through association with the activating signaling protein FcR gamma (5). In mouse, a splice variant of CD300f (known as DIgR2, with a 7 aa insertion in the ECD) inhibits CD4+ T cell activation and in vivo Th1 and CTL responses (9). CD300f is upregulated on monocytes surrounding experimentally-induced spinal cord demyelination and functions as a negative regulator of inflammation in the CNS (10).

References

  1. Clark, G.J. et al. (2009) Trends Immunol. 30:209.
  2. Sui, L. et al. (2004) Biochem. Biophys. Res. Commun. 319:920.
  3. Alvarez-Errico, D. et al. (2004) Eur. J. Immunol. 34:3690.
  4. Korver, W. et al. (2009) Leukemia 23:1587.
  5. Izawa, K. et al. (2009) J. Immunol. 183:925.
  6. Alvarez-Errico, D. et al. (2007) J. Immunol. 178:808.
  7. Can, I. et al. (2008) J. Immunol. 180:207.
  8. Izawa, K. et al. (2007) J. Biol. Chem. 282:17997.
  9. Shi, L. et al. (2006) Blood 108:2678.
  10. Xi, H. et al. (2010) J. Exp. Med. 207:7.

Long Name

Leukocyte Mono Ig-like Receptor 3

Alternate Names

CD300f, CD300LF, CLIM1, CLM1, DIgR2, IGSF13, IREM-1, LMIR3, NKIR, Pigr3

Entrez Gene IDs

146722 (Human); 246746 (Mouse)

Gene Symbol

CD300LF

Additional CD300f/LMIR3 Products

Product Documents for Human CD300f/LMIR3 Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human CD300f/LMIR3 Antibody

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.